Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Amgen team up for brain biomarkers
December 2013
EDIT CONNECT

SHARING OPTIONS:

EMERYVILLE, Calif.—KineMed Inc. has inked an agreement with Amgen under which KineMed will apply its mass spectrometric Dynamic Proteomics platform to study brain protein homeostasis links to neurodegenerative disease. The biomarker platform will enable Amgen to track and study synthesis and clearance rates of pathogenic proteins in the brain. No financial details were released.

“Normal brain aging and neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases, are characterized by the accumulation of misfolded proteins in the brain. Diagnostic tests have not previously been available that reflect the underlying dynamics of the proteins believed to play a causal role in neurodegeneration. This has been a major obstacle in developing drugs that slow the accumulation of these misfolded proteins,” said Dr. Patrizia Fanara, vice president of Neuroscience at KineMed and principal investigator for this study.
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.